Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial looked at nemolizumab — a medicine given by injection — in people with atopic dermatitis (eczema). A total of 226 people took part, split into four groups: 57 received a placebo (a dummy injection with no active medicine), 55 received a 10 mg dose of nemolizumab, 57 received a 30 mg dose, and 57 received a 90 mg dose. The trial ran for 24 weeks. The main thing researchers were measuring was the change in a standard eczema severity score called EASI (which rates redness, skin thickening, scratching marks, and skin hardening across four body areas on a scale of 0 to 72, where higher means worse). Secondary measurements included itch intensity, sleep disruption, and another overall eczema score called SCORAD. The reported data shows that, by week 24, the EASI score had changed from the starting point by an average of −58.4% in the placebo group, −72.2% in the 10 mg nemolizumab group, −73.4% in the 30 mg group, and −69.2% in the 90 mg group (negative numbers mean the score went down from where it started). For the itch scale (called PCS), the number of participants whose itch reached the "none to mild" range at week 24 was 13 out of 57 in the placebo group, 23 out of 55 in the 10 mg group, 31 out of 57 in the 30 mg group, and 20 out of 57 in the 90 mg group. The reported data shows that the overall eczema score SCORAD also changed from the starting point — by −42.6% for placebo, −60.8% for the 10 mg group, −62.5% for the 30 mg group, and −55.9% for the 90 mg group. For sleep disruption (rated on a 0–10 scale), the reported percentage changes from the starting point were −50.7% for placebo, −75.4% for 10 mg, −76.2% for 30 mg, and −74.9% for 90 mg. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 31449914) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Eczema Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years old or older (or older if the legal adult age in your country is higher)
- You have had chronic eczema (atopic dermatitis) for at least 2 years before your visit
- Your eczema scores at least 12 on a standard medical scale that measures how much of your body is affected and how severe it is (confirm with trial site)
- A doctor rates your eczema as moderately severe or worse using a standard assessment scale (confirm with trial site)
- Your eczema covers at least 10% of your body surface area
- You have had severe itching on at least 3 out of the last 7 days before your visit
- You have tried creams or ointments for your eczema in the last 6 months and they have not worked well enough
- If you are a woman who could become pregnant, you must agree to use effective contraception throughout the trial and for 120 days after your last dose, or remain completely abstinent during that time
Who may not be able to join:
- You weigh less than 45 kg (about 99 lbs)
- You have asthma that required a hospital stay in the last 12 months, has not been well controlled in the last 3 months, or where a breathing test shows your lung function is below 80% of the expected level
- You have had a bacterial or viral skin infection within 1 week before your screening visit or during the lead-in period of the trial
- You have had any infection that needed treatment with antibiotics or other anti-infection medicines (taken by mouth or injection) within 1 week before your screening visit or during the lead-in period
- You have had a bad reaction to certain standard steroid creams used for eczema, or there is a medical reason why those creams should not be used on you
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
4 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percent Change From Baseline in Eczema Area and Severity Index (EASI) at Week 24
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.